Free Trial
NYSE:AIM

AIM ImmunoTech (AIM) Stock Price, News & Analysis

AIM ImmunoTech logo
$0.21 +0.02 (+8.42%)
As of 01/17/2025 04:00 PM Eastern

About AIM ImmunoTech Stock (NYSE:AIM)

Key Stats

Today's Range
$0.20
$0.22
50-Day Range
$0.19
$0.26
52-Week Range
$0.16
$0.62
Volume
920,729 shs
Average Volume
566,748 shs
Market Capitalization
$13.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75
Consensus Rating
Buy

Company Overview

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM ImmunoTech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
37th Percentile Overall Score

AIM MarketRank™: 

AIM ImmunoTech scored higher than 37% of companies evaluated by MarketBeat, and ranked 765th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AIM ImmunoTech has only been the subject of 2 research reports in the past 90 days.

  • Read more about AIM ImmunoTech's stock forecast and price target.
  • Earnings Growth

    Earnings for AIM ImmunoTech are expected to decrease in the coming year, from ($0.30) to ($0.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AIM ImmunoTech is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AIM ImmunoTech is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AIM ImmunoTech has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for AIM.
  • Dividend Yield

    AIM ImmunoTech does not currently pay a dividend.

  • Dividend Growth

    AIM ImmunoTech does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for AIM.
  • News Sentiment

    AIM ImmunoTech has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for AIM ImmunoTech this week, compared to 2 articles on an average week.
  • Search Interest

    Only 4 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AIM ImmunoTech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,497.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.02% of the stock of AIM ImmunoTech is held by insiders.

  • Percentage Held by Institutions

    Only 12.02% of the stock of AIM ImmunoTech is held by institutions.

  • Read more about AIM ImmunoTech's insider trading history.
Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

AIM Stock News Headlines

AIM ImmunoTech highlights 2024 milestones achieved
Comparing Mesoblast (NASDAQ:MESO) and AIM ImmunoTech (NYSE:AIM)
Free Stock Ticker Inside: This Indicator Caught Nvidia’s Rallies
I’m not one to make super bold statements… But today, I’m making an exception. Because I’m 100% convinced this is the best indicator I’ve used for trading Nvidia… Don’t believe me? Just take a look at the last two rallies: This powerful indicator caught both moves almost perfectly.
Analyzing AIM ImmunoTech (NYSE:AIM) & Mesoblast (NASDAQ:MESO)
See More Headlines

AIM Stock Analysis - Frequently Asked Questions

AIM ImmunoTech's stock was trading at $0.1980 at the beginning of the year. Since then, AIM stock has increased by 8.0% and is now trading at $0.2138.
View the best growth stocks for 2025 here
.

AIM ImmunoTech Inc. (NYSE:AIM) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.05. The business had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative net margin of 12,594.21% and a negative trailing twelve-month return on equity of 421.73%.

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), iBio (IBIO), Vaxart (VXRT), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO) and T2 Biosystems (TTOO).

Company Calendar

Last Earnings
11/15/2023
Today
1/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Employees
20
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$2.75
High Stock Price Target
$4.50
Low Stock Price Target
$1.00
Potential Upside/Downside
+1,186.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-28,960,000.00
Net Margins
-12,594.21%
Pretax Margin
-12,594.21%

Debt

Sales & Book Value

Annual Sales
$200,000.00
Book Value
$0.20 per share

Miscellaneous

Free Float
63,766,000
Market Cap
$13.64 million
Optionable
Not Optionable
Beta
-0.36

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NYSE:AIM) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners